ACHV
ACHIEVE LIFE SCIENCES, INC.
$5.52
0.00%
$566.7M
No data for this timeframe.
Vol
Market Cap$566.7M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders34 funds
Inst. Value$33.4M
Inst. Activity4 buys / 2 sells
SEC Reports6
Press Releases4
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. DE·CIK 0000949858·Prev Close $5.52
Recent Activity
Jun 20, 2026
fda_pdufa
PDUFA: ACHV — cytisinicline in nicotine dependence for smoking cessation in adults — 2026-06-20
FDA target action date 2026-06-20 for ACHV (ACHIEVE LIFE SCIENCES, INC.). Drug: cytisinicline. Indic
Jun 11, 2026
SEC
A mixed institutional cluster in ACHV for Q3 2025: two mega-passive buyers (State Street, BofA) added small positions to
INST-CLUSTER — Impact 5/10
Jun 2, 2026
SEC
Achieve Life Sciences appointed Jeff Farrow and Dr. Reid Waldman as directors effective May 29, 2026. Both receive stand
8-K — Impact 2/10
May 29, 2026
Insider
Waldman Reid Alexander was granted 47,250 shares
Director
May 29, 2026
Insider
Farrow Jeffrey S was granted 47,250 shares
Director
May 22, 2026
SEC
The SEC declared effective Achieve Life Sciences' S-3 registration statement (File No. 333-295798) on May 21, 2026, cove
EFFECT — Impact 6/10
May 11, 2026
Insider
Martin Christopher Nathan was granted 47,250 shares
Director
Inst.
Hudson Bay Capital Management — ADD
84,896 shares ($249.6K)
Price Targets
$13.11
+137.5% upside
Strong Buy
Current $5.52
Low $9.00
Median $12.00
High $21.00
9 analysts
$9.00
$21.00
Analyst Ratings
2Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 21, 2026 | Canaccord Genuity | INITIATE | Buy |
| Apr 16, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 25, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.15 ▲ +54.5% | $-0.22 — $-0.11 | 59% YoY | 8 |
| Next Q | $-0.16 ▲ +51.2% | $-0.26 — $-0.10 | 42% YoY | 8 |
| Current FY | $-0.69 ▲ +47.5% | $-0.95 — $-0.52 | 45% YoY | 8 |
| Next FY | $-0.46 ▲ +55.3% | $-0.85 — $0.11 | 33% YoY | 8 |
Latest Reports
BEARISH
INST-CLUSTER
5/10
A mixed institutional cluster in ACHV for Q3 2025: two mega-passive buyers (State Street, BofA) added small positions to
Jun 11, 2026
NEUTRAL
8-K
2/10
Achieve Life Sciences appointed Jeff Farrow and Dr. Reid Waldman as directors effective May 29, 2026. Both receive stand
Jun 2, 2026
BULLISH
Press
7/10
Achieve Life Sciences presented comprehensive long-term safety data from the ORCA-OL study at ATS 2026, showing cytisini
May 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | DOUBLED |
| FRANKLIN RESOURCES INC | $12.8M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.5M | — |
| MARSHALL WACE, LLP | $3.0M | ADD |
| RAYMOND JAMES FINANCIAL INC | $1.9M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | Waldman Reid | A | $0.00 |
| May 29, 2026 | Farrow Jeffrey | A | $0.00 |
| May 11, 2026 | Martin Christopher | A | $0.00 |
| Apr 18, 2026 | Goldberg Andrew | A | $0.00 |
| Apr 18, 2026 | Goldberg Andrew | A | $0.00 |
34 institutional holders with $33.4M total value (11,395,222 shares) as of 2026-Q1. Top holders: ROYAL, FRANKLIN, VANGUARD. Net buying activity: 4 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 126 | $0.00 | 0.0% | DOUBLED +6179.8% |
| 2 | FRANKLIN RESOURCES INC | 4,369,193 | $12.8M | 38.4% | DOUBLED +18747.4% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2,204,714 | $6.5M | 19.4% | — |
| 4 | MARSHALL WACE, LLP | 1,019,281 | $3.0M | 9.0% | ADD +31.5% |
| 5 | RAYMOND JAMES FINANCIAL INC | 641,925 | $1.9M | 5.6% | ADD +57.1% |
| 6 | TWO SIGMA INVESTMENTS, LP | 588,551 | $1.7M | 5.2% | ADD +70.5% |
| 7 | BlackRock, Inc. | 439,360 | $1.3M | 3.9% | — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 383,683 | $1.1M | 3.4% | — |
| 9 | VANGUARD FIDUCIARY TRUST CO | 316,177 | $929.6K | 2.8% | — |
| 10 | STATE STREET CORP | 254,457 | $748.1K | 2.2% | ADD +39.6% |
| 11 | CITADEL ADVISORS LLC | 202,800 | $596.2K | 1.8% | — |
| 12 | GOLDMAN SACHS GROUP INC | 152,952 | $449.7K | 1.3% | — |
| 13 | WELLS FARGO & COMPANY/MN | 101,971 | $299.8K | 0.9% | — |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 84,900 | $249.6K | 0.7% | — |
| 15 | Hudson Bay Capital Management LP | 84,896 | $249.6K | 0.7% | ADD +25.5% |
| 16 | BANK OF AMERICA CORP /DE/ | 70,684 | $207.8K | 0.6% | DOUBLED +193.9% |
| 17 | MORGAN STANLEY | 70,378 | $206.9K | 0.6% | DOUBLED +135.0% |
| 18 | Brevan Howard Capital Management LP | 54,508 | $160.3K | 0.5% | — |
| 19 | DIMENSIONAL FUND ADVISORS LP | 52,420 | $154.1K | 0.5% | — |
| 20 | BARCLAYS PLC | 48,067 | $141.3K | 0.4% | NEAR_EXIT -99.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Hudson Bay Capital Management LP | ADD | 67,663 | 84,896 | +25.5% | $249.6K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 24,054 | 70,684 | +193.9% | $207.8K | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 20,000 | 43,000 | +115.0% | $126.4K | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 75,169 | 37,760 | -49.8% | $111.0K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 152,460 | 27,952 | -81.7% | $82.2K | 2026-Q1 |
| HRT FINANCIAL LP | ADD | 18,858 | 31,579 | +67.5% | $92.00 | 2026-Q1 |
| FRANKLIN RESOURCES INC | DOUBLED | 23,182 | 4,369,193 | +18747.4% | $21.7M | 2025-Q4 |
| MARSHALL WACE, LLP | ADD | 774,853 | 1,019,281 | +31.5% | $5.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 439,064 | 748,616 | +70.5% | $3.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 310,764 | 152,460 | -50.9% | $757.7K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 33,647 | 79,061 | +135.0% | $392.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 47,409 | 24,054 | -49.3% | $119.5K | 2025-Q4 |
| STATE STREET CORP | ADD | 157,884 | 220,384 | +39.6% | $694.2K | 2025-Q3 |
| Alyeska Investment Group, L.P. | NEAR_EXIT | 3,504,333 | 178,389 | -94.9% | $561.9K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 33,731 | 47,409 | +40.6% | $149.3K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 106,297 | 33,647 | -68.3% | $106.0K | 2025-Q3 |
| FRANKLIN RESOURCES INC | NEAR_EXIT | 4,459,014 | 23,182 | -99.5% | $38.7K | 2025-Q3 |
| PNC FINANCIAL SERVICES GROUP, INC. | NEAR_EXIT | 3,983 | 826 | -79.3% | $2.6K | 2025-Q3 |
| CWM, LLC | TRIM | 3,871 | 1,702 | -56.0% | $5.00 | 2025-Q3 |
| BARCLAYS PLC | NEAR_EXIT | 1,716 | 1 | -99.9% | $3.00 | 2025-Q3 |
| FRANKLIN RESOURCES INC | ADD | 2,458,935 | 4,459,014 | +81.3% | $10.1M | 2025-Q2 |
| Alyeska Investment Group, L.P. | DOUBLED | 421,000 | 3,504,333 | +732.4% | $7.9M | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 1,717,014 | 2,149,877 | +25.2% | $4.9M | 2025-Q2 |
| RAYMOND JAMES FINANCIAL INC | ADD | 187,840 | 295,058 | +57.1% | $666.8K | 2025-Q2 |
| STATE STREET CORP | TRIM | 453,420 | 157,884 | -65.2% | $356.8K | 2025-Q2 |
10 unique insiders with 12 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Waldman Reid Alexander | Director | AWARD | 47,250 | — | — |
| May 29, 2026 | Farrow Jeffrey S | Director | AWARD | 47,250 | — | — |
| May 11, 2026 | Martin Christopher Nathan | Director | AWARD | 47,250 | — | — |
| Apr 18, 2026 | Goldberg Andrew D. | CEO and President | AWARD | 1,800,965 | — | — |
| Apr 18, 2026 | Goldberg Andrew D. | CEO and President | AWARD | 3,601,929 | — | — |
| Apr 18, 2026 | Goldberg Andrew D. | CEO and President | AWARD | 11,706,270 | — | — |
| Jan 28, 2026 | Oki Mark K | Chief Financial Officer | AWARD | 180,000 | — | — |
| Jan 28, 2026 | Xinos Jaime | Chief Commercial Officer | AWARD | 180,000 | — | — |
| Jan 28, 2026 | Donnelly Craig | Chief Operations Officer | AWARD | 180,000 | — | — |
| Jan 28, 2026 | Stewart Richard Alistair | Chief Executive Officer | AWARD | 645,000 | — | — |
| Jan 28, 2026 | Rubinstein Mark Lawrence | Chief Medical Officer | AWARD | 180,000 | — | — |
| Jan 28, 2026 | Wan Jerry | Principal Accounting Officer | AWARD | 70,300 | — | — |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 2 mixed, 1 neutral. Avg impact: 5.5/10.
BEARISH
INST-CLUSTER
5/10
A mixed institutional cluster in ACHV for Q3 2025: two mega-passive buyers (State Street, BofA) adde
Jun 11, 2026
NEUTRAL
8-K
2/10
Achieve Life Sciences appointed Jeff Farrow and Dr. Reid Waldman as directors effective May 29, 2026
Jun 2, 2026
BEARISH
EFFECT
6/10
The SEC declared effective Achieve Life Sciences' S-3 registration statement (File No. 333-295798) o
May 22, 2026
MIXED
8-K
7/10
Achieve Life Sciences reported Q1 2026 net loss of $10.2M ($0.19/share) vs $12.8M ($0.37/share) in Q
May 12, 2026
MIXED
PRESS-RELEASE
6/10
Achieve Life Sciences reported Q1 2026 EPS of -$0.28, beating consensus of -$0.30 by 6.7%. The compa
May 12, 2026
BEARISH
8-K
7/10
Achieve Life Sciences (ACHV) raised $180 million through a private placement of common stock, pre-fu
Apr 16, 2026
BULLISH
7/10
Achieve Life Sciences presented comprehensive long-term safety data from the ORCA-OL study at ATS 20
May 19, 2026
BULLISH
5/10
Achieve Life Sciences announced a $354 million private placement financing, including $180 million u
Apr 16, 2026
MIXED
6/10
Achieve Life Sciences announced the successful transfer of cytisinicline manufacturing to U.S.-based
Apr 15, 2026
MIXED
6/10
Achieve Life Sciences reported Q4 and full-year 2025 financial results, highlighted by a net loss of
Mar 24, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 2 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.11 mean target
+137.5% upside
Strong Buy (3.00)
$9.00 Low
$21.00 High
| Metric | Value |
|---|---|
| Current Price | $5.52 |
| Target Low | $9.00 |
| Target Mean | $13.11 |
| Target Median | $12.00 |
| Target High | $21.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.15 | $-0.22 | $-0.11 | 59.5% | +54.5% | 6↑ 0↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$-0.16 | $-0.26 | $-0.10 | 42.0% | +51.2% | 6↑ 0↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-0.69 | $-0.95 | $-0.52 | 44.6% | +47.5% | 7↑ 0↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-0.46 | $-0.85 | $0.11 | 33.0% | +55.3% | 6↑ 0↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.150 | |
| 7d ago | $-0.171 | +0.021 |
| 30d ago | $-0.330 | +0.180 |
| 60d ago | $-0.323 | +0.173 |
| 90d ago | $-0.323 | +0.173 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 21, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Apr 16, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 20, 2026
fda_pdufa
PDUFA: ACHV — cytisinicline in nicotine dependence for smoking cessation in adults — 2026-06-20
FDA target action date 2026-06-20 for ACHV (ACHIEVE LIFE SCIENCES, INC.). Drug: cytisinicline. Indication: nicotine dependence for smoking cessation i
Jun 2, 2026
other
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approva
May 28, 2026
short_volume
Short Volume: ACHV — 62.2% short (0.7M / 1.1M)
Short: 678,627 | Exempt: 424 | TRF Vol: 1,091,681 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
May 19, 2026
fda
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
<p align="center"><em>ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA</em></p>
May 19, 2026
short_volume
Short Volume: ACHV — 57.0% short (0.3M / 0.6M)
Short: 329,356 | Exempt: 3,934 | TRF Vol: 577,524 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
May 12, 2026
other
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior Vice President of Commercial and Vice President of
May 12, 2026
earnings
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="center"><em>Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants</em
May 12, 2026
earnings_calendar
ACHV Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
earnings_calendar
ACHV Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
earnings
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026
<p>SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty phar
Apr 17, 2026
short_interest
FTD: ACHV — 244,903 shares ($1.2M) failed to deliver
Settlement: 20260417, Price: $4.81, FTD Value: $1,177,983.43, ACHIEVE LIFE SCIENCES INC COM
Apr 16, 2026
other
Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors
<p align="center"><em>Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors </em></p>
Apr 16, 2026
activist
Achieve Life Sciences Announces Up to $354 Million Private Placement
<p align="center"><strong><em>$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA App
Apr 15, 2026
Clinical Trial
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Phase Phase 3 — COMPLETED
Apr 15, 2026
contract
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
<p align="center"><em>Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability</em></p>
Mar 27, 2026
short_volume
Short Volume: ACHV — 59.6% short (0.4M / 0.7M)
Short: 419,909 | Exempt: 226 | TRF Vol: 704,442 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)